新型治疗范式:膜性肾病
原发性膜性肾病是白人成人肾病综合征的首位病因,多由抗磷脂酶A2受体抗体介导。本文综述现有免疫抑制治疗(环磷酰胺联合激素、利妥昔单抗、钙调神经磷酸酶抑制剂)的获益与局限,并介绍靶向B细胞和浆细胞的新型疗法。
要点
- 持续肾病综合征且最大保守治疗无反应者需用免疫抑制治疗,但最佳方案尚未确立。
- 环磷酰胺联合激素有效但不良作用限制使用,钙调神经磷酸酶抑制剂复发率高且有肾毒性。
- 靶向B细胞和浆细胞的新型疗法在难治或不耐受者中初步显示疗效与安全性。
核心结论
- 经典免疫抑制剂有效但不良作用限制使用,部分患者对标准治疗无反应,靶向B细胞和浆细胞的新疗法初步结果令人鼓舞。
研究设计与样本
- 本文为简要综述,讨论当前膜性肾病治疗方法的获益与局限,并描述针对其发病机制的新兴疗法。
主要发现
- 原发性膜性肾病通常由抗磷脂酶A2受体抗体引起,近期发现多个新靶抗原。
- 持续肾病综合征且最大保守治疗(包括肾素-血管紧张素系统阻滞剂)无反应者需用免疫抑制治疗。
- 环磷酰胺联合激素有效但可能引起临床相关不良作用,限制其使用。
- 利妥昔单抗有效且安全性较好,钙调神经磷酸酶抑制剂复发率高且有肾毒性。
- 高达30%的患者对标准治疗无反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary membranous nephropathy (MN) is a kidney-specific autoimmune glomerular disease and the leading cause of nephrotic syndrome (NS) in White adults, usually caused by antiphospholipase A2 receptor (PLA2R) antibodies, although several new target antigens have been recently identified. It is characterized by the diffuse thickening of the glomerular basement membrane secondary to immune complex deposition. In patients with persistent NS without response to maximizing conservative therapy including the use of renin-angiotensin system (RAS) blockers, the use of immunosuppressive agents is warranted. However, the optimal immunosuppressive treatment has not yet been established. Classical immunosuppressants, such as cyclophosphamide plus steroids, are effective but may cause clinically relevant adverse effects, limiting their use. Rituximab offers efficacy with a better safety profile whereas calcineurin inhibitors (CNIs) are marred by high relapse rates and nephrotoxicity. Nevertheless, up to 30% of patients fail to respond to standard therapy. Novel and specific therapies targeting B cells and plasma cells have shown encouraging preliminary results, in terms of clinical efficacy and safety profile, especially in patients with poor tolerance or refractory to conventional treatments. In this brief review, we discuss the benefits and limitations of the current therapeutic approach to MN and describe emerging novel therapies that target its pathogenesis.
引用
- Rojas-Rivera JE, Ortiz A, Fervenza FC, et al. Novel Treatments Paradigms: Membranous Nephropathy. Kidney Int Rep. 2023. PMID: 36938069. doi:10.1016/j.ekir.2022.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。